相似文献
1
Are drug eluting stents really worth the money?
Heart. 2006 Jan;92(1):5-7. doi: 10.1136/hrt.2005.066316. Epub 2005 Jun 6.
2
Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.
Circulation. 2004 Aug 3;110(5):472-4. doi: 10.1161/01.CIR.0000136820.77558.B1.
3
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.
Heart. 2006 Jan;92(1):68-74. doi: 10.1136/hrt.2004.053850. Epub 2005 Apr 14.
4
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Circulation. 2004 Aug 3;110(5):508-14. doi: 10.1161/01.CIR.0000136821.99814.43. Epub 2004 Jul 19.
5
Drug-eluting stents: cost versus clinical benefit.
Circulation. 2003 Jun 24;107(24):3003-7. doi: 10.1161/01.CIR.0000078025.19258.28.
6
Drug-eluting stents: costs versus clinical benefit.
Circulation. 2003 Jun 24;107(24):3008-11. doi: 10.1161/01.CIR.0000079018.84618.0E.
7
Drug eluting stents: maximising benefit and minimising cost.
Heart. 2003 Feb;89(2):127-31. doi: 10.1136/heart.89.2.127.
8
Hippocrates revisited: the evidence for drug-eluting stents.
Circulation. 2003 Jun 24;107(24):3012-4. doi: 10.1161/01.CIR.0000079940.15982.75.
9
Can we afford to eliminate restenosis? Can we afford not to?
J Am Coll Cardiol. 2004 Feb 18;43(4):513-8. doi: 10.1016/j.jacc.2003.11.020.
10
Drug-eluting stents substantially lower rate of restenosis.
Rep Med Guidel Outcomes Res. 2003 Oct 17;14(20):7-9.
引用本文的文献
1
Trends in hospital discharges, management and in-hospital mortality from acute myocardial infarction in Switzerland between 1998 and 2008.
BMC Public Health. 2013 Mar 25;13:270. doi: 10.1186/1471-2458-13-270.
本文引用的文献
1
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
J Am Coll Cardiol. 2005 Apr 19;45(8):1172-9. doi: 10.1016/j.jacc.2004.10.075.
2
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.
Heart. 2006 Jan;92(1):68-74. doi: 10.1136/hrt.2004.053850. Epub 2005 Apr 14.
3
One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.
Heart. 2005 Apr;91(4):507-12. doi: 10.1136/hrt.2004.034454.
4
Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
Am J Cardiol. 2005 Mar 15;95(6):709-15. doi: 10.1016/j.amjcard.2004.11.020.
5
Economic evaluation of sirolimus-eluting stents.
CMAJ. 2005 Feb 1;172(3):345-51. doi: 10.1503/cmaj.1041062.
6
Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study.
BMJ. 2005 Feb 26;330(7489):441. doi: 10.1136/bmj.38335.390718.82. Epub 2005 Jan 21.
7
Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents.
Circulation. 2005 Jan 25;111(3):321-7. doi: 10.1161/01.CIR.0000153356.72810.97. Epub 2005 Jan 17.
8
Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
J Am Coll Cardiol. 2005 Jan 18;45(2):198-203. doi: 10.1016/j.jacc.2004.05.089.
9
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
Circulation. 2004 Apr 27;109(16):1942-7. doi: 10.1161/01.CIR.0000127110.49192.72. Epub 2004 Apr 12.
10
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.
Circulation. 2004 Feb 10;109(5):634-40. doi: 10.1161/01.CIR.0000112572.57794.22.
Zotero 插件